Feed aggregator

"Long Haul" COVID-19 Associated With More Medication Use, Higher Risk of Death

Biospace news - Fri, 04/23/2021 - 02:00
A new study suggests that many patients with long-term COVID-19 symptoms still experience health issues six months following infection, are survivors with "long haul" disease have a greater risk of dying and use a more significant number of medications than patients who have fully recovered from ...

Molecular Partners Files $100 Million IPO to Advance COVID-19 and Cancers Therapies

Biospace news - Fri, 04/23/2021 - 02:00
Molecular Partners announced yesterday it has filed for a $100 million initial public offering with the Securities and Exchange Commission in the U.S., funding which will go toward supporting the company's work in the development of protein-based treatments for COVID-19 and various cancers.

Pfizer-BioNTech, Moderna Vaccines Effective Against Variants and More COVID-19 News

Biospace news - Fri, 04/23/2021 - 02:00
With the U.S. Food and Drug Administration’s vaccines advisory committee meeting being held today to discuss the Johnson & Johnson vaccine and blood clotting, there’s even more interest in what’s going on in the pandemic than usual. Here’s a look at some of the top stories.

Vaccines Ramp Up While Variants Run Rampant

Biospace news - Fri, 04/23/2021 - 02:00
At the end of February, the U.S. was averaging 65,686 new COVID-19 cases per day. Fast-forward two months and that number is nearly identical at 64,814.

Research Roundup: Immune Cell Differences in Asymptomatic Versus Severe COVID-19 and More

Biospace news - Fri, 04/23/2021 - 02:00
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.

New Drug Boosts Brain Cell Cleanup to Combat Neurodegenerative Diseases

Biospace news - Fri, 04/23/2021 - 02:00
Researchers from Albert Einstein’s College of Medicine are excited with the recently published findings of an experimental drug that reversed key symptoms of Alzheimer’s disease in mice.

Ocugen On Track to Bring Bharat Biotech's COVAXIN to US Market With Strong Data

Biospace news - Fri, 04/23/2021 - 02:00
Ocugen’s plan to bring a COVID-19 vaccine developed by India-based Bharat Biotech later this year remains on track following an interim analysis of Phase III data that shows the vaccine demonstrated a 78% efficacy against mild to moderate infection and 100% efficacy against severe COVID-19.

BioSpace Movers & Shakers, April 23

Biospace news - Fri, 04/23/2021 - 02:00
Biopharma and life sciences companies strengthen their boards and leadership teams with these Movers & Shakers.

Sponsored | Business Transformation during a Pandemic: Q&A about Jubilant Biosys’ bold plans wit...

Biospace news - Fri, 04/23/2021 - 02:00
This is by far the most exciting time in our history as Jubilant Biosys, and certainly the most exciting message Biosys has ever announced simply because of the sheer scale of transformation that we’ve taken on. It’s massive, very achievable, and ultimately truly transformative for us as colleagu...

CureVac Swiss AG initiates rolling submission process for mRNA-based COVID-19 vaccine candidate, CVnCoV, with Swissmedic

World Pharma News - Thu, 04/22/2021 - 12:00
The CureVac Swiss AG, the Swiss subsidiary of CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), announced initiation of a rolling submission for CVnCoV, the company's mRNA based COVID-19 vaccine candidate, for the use in Switzerland.

Updated results on coronavirus vaccination effectiveness

World Pharma News - Thu, 04/22/2021 - 10:00
Several weeks following the publication of the large real-world COVID-19 vaccine effectiveness study by the Clalit Research Institute in Collaboration with Harvard University in the New England Journal of Medicine (NEJM), additional results focusing on vaccine effectiveness in specific sub-populations have now been published.

Biogen’s Alzheimer’s Drug is in the Home Stretch, but Can it Win Approval?

Biospace news - Thu, 04/22/2021 - 02:00
The long and strange journey of Biogen’s Alzheimer’s drug aducanumab is coming to an end. Whether it will be a complete ending—with the U.S. FDA rejecting it—or a new chapter, with an approval, remains to be seen.

Ortho Dermatologics Announces More Positive Data for New Acne Vulgaris Therapy

Biospace news - Thu, 04/22/2021 - 02:00
On the back of the two positive Phase III trials, Ortho said it will submit a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) in the second half of 2022.

Moderna Execs Sell Off Some Stock Shares to Capitalize on Gains, While Index Declines

Biospace news - Thu, 04/22/2021 - 02:00
Shareholders have been pleased with the company’s mRNA vaccine, but some, including the company’s cofounder, are cashing in on their stock gains.

FDA Approves GSK’s Checkpoint Inhibitor Jemperli for Endometrial Cancer

Biospace news - Thu, 04/22/2021 - 02:00
The approval was specifically for patients with recurrent or advanced endometrial cancer who had progressed on or after previous treatment with platinum-based chemotherapy and whose cancers have a dMMR genetic anomaly.

Aptorum Enters Agreement With Yale to Develop, Investigate Novel Immunomodulators

Biospace news - Thu, 04/22/2021 - 02:00
Clinical-stage biopharmaceutical company, Aptorum Group Limited, announced today that it has entered into a material transfer and option agreement with Yale University to study preclinical stage novel immunomodulators targeting autoimmune and oncology diseases.

Newly-Launched Centessa Pharmaceuticals Already Planning $100 Million IPO

Biospace news - Thu, 04/22/2021 - 02:00
Two months after Centessa Pharmaceuticals launched following the merger of 10 private biotech companies, the company is already eying a $100 million splash on the Nasdaq stock exchange.

J&J and AstraZeneca's Vaccine Woes Push Novavax Cautiously Into the Light

Biospace news - Thu, 04/22/2021 - 02:00
Novavax is plugging along to get their COVID-19 vaccine candidate, NVX-CoV2373, through late-stage clinical trials and authorized in the U.S. and elsewhere.

Global Roundup: Phico Therapeutics Wins CARB-X Funding for Bacteriophage Drug

Biospace news - Thu, 04/22/2021 - 02:00
Biopharma and life sciences companies from around the globe provide updates on their businesses and pipelines.

Seed Health and Anavo Therapeutics Launch With Millions in in Early Financings

Biospace news - Thu, 04/22/2021 - 02:00
New Series A financing rounds have been announced in the last two days, with Seed Health leading the pack followed by Anavo Therapeutics.